Clever Leaves (NASDAQ: CLVRW) is a vertically integrated pharmaceutical company specializing in the cultivation, processing and distribution of medical cannabis and cannabinoid-derived products. The company operates under EU-GMP and ISO certifications, ensuring consistent production of high-purity tetrahydrocannabinol (THC) and cannabidiol (CBD) formulations. Clever Leaves focuses on developing botanical and semi-synthetic therapies to support patient treatment programs and clinical research initiatives.
The company maintains outdoor cultivation operations in Colombia, complemented by indoor and greenhouse facilities in Portugal and a processing and manufacturing site in Massachusetts, USA. This multi-jurisdictional footprint allows Clever Leaves to leverage low-cost production environments and rigorous quality controls. Extracted cannabinoid concentrates are formulated into oils, capsules and inhalation products for distribution to licensed pharmaceutical partners and government programs.
Clever Leaves serves regulated markets across North America, Europe and Latin America, including active supply agreements in Germany, Canada and select U.S. states. Its portfolio of product offerings extends from raw botanical extracts to finished dosage forms tailored for patient-centric applications. The company also collaborates with academic and clinical institutions to advance research on novel therapeutic uses of cannabinoids.
With GMP-compliant facilities spanning three continents, Clever Leaves is positioned to capitalize on the growing global demand for standardized medical cannabis. The company’s operational strategy emphasizes scalable cultivation practices, traceable supply chain management and ongoing investment in extraction technology. These capabilities support its goal of delivering affordable, high-quality cannabinoid medicines to patients and healthcare providers worldwide.
AI Generated. May Contain Errors.
